|
Orthologous residues
|
|
RasGRF1 (human): S929‑p, RasGRF1 iso3 (human): S911‑p, RasGRF1 (mouse): S916‑p, RasGRF1 (rat): S898‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling, immunoprecipitation, mutation of modification site, phosphopeptide mapping
|
|
Relevant cell lines - cell types - tissues:
3T3 (fibroblast), COS (fibroblast)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
monkey, mouse
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
PKACa (human)
|
pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
forskolin, IBMX
|
|
|
|
increase
|
|
|
carbachol
|
|
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
activation
|
|
Comments:
necessary but not sufficient for RasGRF1 activation
|
